NCT02228395

Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers

A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 Following Oral Dose Capsules in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Biogen · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers

Detailed description

This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	PF-04958242	Administered as specified in treatment arm
DRUG	Placebo	Administered as specified in treatment arm

Timeline

• Start date: 2014-09-22
• Primary completion: 2014-11-13
• Completion: 2014-11-13
• First posted: 2014-08-29
• Last updated: 2020-01-07
• Results posted: 2015-12-17

Locations

1 site across 1 country: United States